Date | Price Target | Rating | Analyst |
---|---|---|---|
2/1/2022 | $27.00 → $15.00 | Overweight | Morgan Stanley |
- Global oncology expert brings deep insight in colorectal cancer and role of CTLA-4 therapy as a cornerstone for combination immunotherapy - SAN DIEGO and SUZHOU, China, March 07, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Heinz-Josef Lenz, M.D., FACP, to its Scientific and Strategic Advisory Board (the "SAB"). Dr. Lenz is the Associate Director for Clinical Research and Co-leader of the Translational Science Program at the USC Norris Comprehensive Cancer Center, part of Keck Medicine of USC and Co-Director of the Center for Cancer Drug Development a
- Brings deep insight in tumor-specific Treg depletion for anti-CTLA-4 therapies delivered intratumorally to overcome dose dependent toxicities - - Expertise contributes to Adagene's novel anti-CTLA-4 therapies delivered systemically at higher and repeated doses with compelling safety - SAN DIEGO and SUZHOU, China, March 05, 2023 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Professor Aurélien Marabelle, MD, PhD, to its Scientific and Strategic Advisory Board (the "SAB"). Professor Marabelle is a physician-scientist with expertise in oncology and imm
SAN DIEGO and SUZHOU, China, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Cuong Do, MBA, to Adagene's board of directors (the "Board") as an independent director. He will also serve as an audit committee member. Mr. Do is President and CEO of BioVie Inc., a clinical-stage company developing innovative therapies for Alzheimer's Disease, Parkinson's disease and refractory Ascites. Prior to BioVie, Mr. Do was President of Samsung's Global Strategy Group where he helped to set the strategic direction for Samsung Group's diverse business portfolio, i
Morgan Stanley reiterated coverage of Adagene with a rating of Overweight and set a new price target of $15.00 from $27.00 previously
– Topline data for anti-CTLA-4 antibody, ADG116, shows compelling clinical safety and complete and partial responses as both a single agent and in combination with anti-PD-1 therapy; results to be presented at SITC 2022 – – Masked, anti-CTLA-4 antibody, ADG126, safely dosed repeatedly up to 20 mg/kg as a single agent with encouraging efficacy signals; results to be presented at ESMO 2022 – – Presentation of combination dosing data with anti-PD-1 therapies in 2022, while dose expansion begins for both ADG116 and ADG126 in targeted tumors – – Submitted regulatory filing for clinical trial of masked, IgG1-based anti-CD137 candidate, ADG206, with greater preclinical potency than the analog of
- Confirmed partial responses (PRs) doubled to four since ASCO GI in MSS CRC patients without liver and peritoneal metastases for overall response rate (ORR) of 24% (4/17) with ADG126 10 mg/kg every three weeks (Q3W) in combination with pembrolizumab - - Median progression-free survival of 8.5 months observed in patients without liver and peritoneal metastases at the ADG126 10 mg/kg Q3W dose - - At the 10 mg/kg dose level, 12-month overall survival (OS) rates were 74% for patients without liver metastases, and 82% for those without liver and peritoneal metastases - - Safety profile maintained, with only 16% Grade 3 TRAEs in patients treated with ADG126 10 mg/kg Q3W in c
SAN DIEGO and SUZHOU, China, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (NASDAQ:ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced the company's participation in several upcoming investor conferences in New York City. Management will host investor meetings and Adagene's Chairman, Chief Executive Officer and President of R&D, Peter Luo, Ph.D., will present at the following events: Morgan Stanley 22nd Annual Global Healthcare Conference Date: Friday, September 6Fireside Chat: 7:45 - 8:20 AM Eastern Time (ET) H.C. Wainwright 26th Annual Global Investment Conference D
- Potential best-in-class therapeutic index for lead candidate anti-CTLA-4 SAFEbody® ADG126 (muzastotug) with higher, more frequent and repeat dosing in combination with Merck's anti-PD-1 therapy KEYTRUDA* (pembrolizumab) to unleash potential efficacy, while maintaining safety comparable to pembrolizumab alone - - Poster planned at European Society of Medical Oncology (ESMO) Congress 2024 in September for ADG126 in combination with pembrolizumab in metastatic microsatellite-stable (MSS) colorectal cancer (CRC) reinforces potential best-in-class profile in larger patient sample - - Differentiated safety profile of ADG126 enables an immunotherapy doublet to combine with standard of care and
HC Wainwright & Co. analyst Arthur He reiterates Adagene (NASDAQ:ADAG) with a Buy and maintains $5 price target.
HC Wainwright & Co. analyst Arthur He reiterates Adagene (NASDAQ:ADAG) with a Buy and maintains $5 price target.
Gainers Liquidia (NASDAQ:LQDA) stock rose 12.7% to $14.5 during Friday's after-market session. The market value of their outstanding shares is at $1.1 billion. Adagene (NASDAQ:ADAG) shares moved upwards by 10.67% to $2.8. The company's market cap stands at $123.6 million. Atara Biotherapeutics (NASDAQ:ATRA) stock moved upwards by 6.95% to $0.6. The market value of their outstanding shares is at $72.2 million. Novo Integrated Sciences (NASDAQ:NVOS) shares increased by 6.64% to $1.12. The company's market cap stands at $21.3 million. IGC Pharma (AMEX:IGC) stock increased by 5.95% to $0.52. The company's market cap stands at $38.8 million. Calidi Biotherapeutics (AMEX:CLDI) shares increas
SC 13D/A - Adagene Inc. (0001818838) (Subject)
SC 13G/A - Adagene Inc. (0001818838) (Subject)
SC 13G - Adagene Inc. (0001818838) (Subject)
6-K - Adagene Inc. (0001818838) (Filer)
6-K - Adagene Inc. (0001818838) (Filer)
6-K - Adagene Inc. (0001818838) (Filer)